|
Patent landscape, scope, and claims: |
United States Patent 3,553,212 Patent Scope, Claims & US Patent Landscape Analysis
Executive summary: Patent US 3,553,212 is a core-compound/process patent with a claim set that determines whether later-made crystalline, formulation, or method-of-use variants can be cleared for generic or follow-on development. A defensible freedom-to-operate (FTO) position depends on (1) mapping each independent and dependent claim element to the target product’s active ingredient identity, physical form, and manufacturing steps, and (2) checking whether the Orange Book (if applicable) lists this patent for any FDA-approved product. Without the claim text (verbatim) or at least the claim list, claim-scope mapping cannot be performed.
What does US Patent 3,553,212 claim and what is its scope?
Short answer: Scope turns on the specific claim language for (a) the chemical identity defined by formulae, substituents, and ranges; (b) process conditions (reagents, temperatures, catalysts, times, pressures); and (c) any product-by-process or intermediate definitions. The independent claims set the practical boundary for design-arounds; dependent claims often cover narrower embodiments such as specific salts, polymorphs, isomers, or step sequences.
What are the independent claims likely covering?
Short answer: For patents of this era (3,xxx,xxx series), independent claims typically cover either:
- a compound defined by structure or broad formula; and/or
- a process for making the compound using defined reaction steps; and/or
- a use category statement that may read like a method-of-use claim.
How should dependent claims be analyzed for FTO?
Dependent claims expand scope by adding limitations. In practice, they matter because:
- If a competitor practices only the independent-claim-level elements but omits a dependent limitation, the dependent claims do not read.
- If dependent claims recite a specific salt, ester, polymorph, or intermediate, they create stronger hooks for litigation over specific product attributes.
Claim-chart requirement for design-around
A proper scope analysis is claim-by-claim, requiring the verbatim claim text. A valid mapping must evaluate:
- Literal infringement element-by-element (and under doctrine of equivalents where relevant)
- Claim construction issues (definitions, open-ended transition words like “comprising”)
- Whether any claim reads on intermediates during manufacture (common in process patents)
How many related US patents are in the US 3,553,212 family?
Short answer: The relevant question is not only “how many,” but which ones share the same specification disclosure and priority dates, and which ones have overlapping claim scope that could block downstream development even if US 3,553,212 is avoided.
What to check in the patent family
For the family tied to US 3,553,212, a landscape view should include:
- Continuations/divisionals
- Continuation-in-part (CIP) that may expand subject matter
- Reissue claims (if any)
- Foreign counterparts (EP/WO) that can inform claim interpretation and prosecution history
How overlapping filings change risk
- If prosecution produced narrower allowed claims, later generics may only be blocked against specific embodiments.
- If earlier broader claims were issued and later narrowed only for compliance, litigation can still target the broader meanings of already-issued independent claims.
Which companies are likely to hold the rights to US 3,553,212 and its continuations?
Short answer: Ownership and assignee changes over decades can shift enforcement risk. The landscape must be anchored to:
- Current assignee or owner for US 3,553,212
- Assignees for continuation/divisional family members
Why assignee mapping affects licensing leverage
- Patent holders with active enforcement patterns increase settlement pressure.
- Firms focused on “evergreen” process improvements can defend manufacturing-only claims even where product composition is contested.
When does US 3,553,212 expire in the United States?
Short answer: Expiration depends on:
- Filing date and term rules in force
- Any Patent Term Adjustment (PTA) or Patent Term Extension (PTE)
- Whether the patent is subject to additional regulatory exclusivity overlays via Orange Book listing (if applicable)
How to compute base term
For US patents, base term generally depends on filing date (pre- vs post-URAA). Accurate expiration requires the patent’s filing date and any adjustments.
Exclusivity timelines vs patent term
If a listed FDA approval is involved, regulatory exclusivities can extend market exclusivity even after patent expiry, and vice versa. This must be checked via the Orange Book listing status.
What is the Orange Book status of US 3,553,212 (is it listed for an FDA-approved drug)?
Short answer: Orange Book listing is determinative for practical generic timing risk because it links the patent to an approved NDA/BLA product and triggers Hatch-Waxman mechanisms (Paragraph IV challenges).
If listed, what does that imply?
- If Orange Book-listed, US 3,553,212 can be the basis of Paragraph IV certifications.
- If not listed, it may still be enforceable, but it does not directly drive the NDA/BLA certification framework.
Does US 3,553,212 enable compound, formulation, or method-of-use protection?
Short answer: The claim type determines enforcement targets:
- Compound claims: block entity-level manufacture/sale of the claimed compound.
- Process claims: block manufacture steps, including during contract manufacturing.
- Formulation claims: block specific dosage forms, excipients, concentrations, or solid-state forms.
- Method-of-use claims: block prescribing or practicing of a specific therapeutic use tied to the claimed invention.
Key FTO decision points
- Are the claims composition-based or are they limited to process steps?
- Are salts/hydrates/polymorphs explicitly claimed?
- Are intermediates claimed, creating additional manufacturing risk?
What formulations are protected by US 3,553,212?
Short answer: Only the claim language can answer this. Formulation coverage typically appears as:
- dosage form limitations (tablet, capsule, suspension, injection)
- excipient selection or concentration ranges
- coating or controlled-release features
- solid-state form restrictions (crystal habit, polymorph, amorphous form)
How to test whether a formulation design-around works
A competitor can potentially avoid formulation claims by:
- using a different salt/polymorph
- changing excipient set outside claimed ranges
- altering manufacturing method to avoid steps tied to a process claim
What generic entry risks exist for products that use the same active ingredient?
Short answer: Generic risk exists when:
- the generic’s active ingredient falls within the compound claim scope, or
- manufacturing uses the claimed process steps (directly or through product-by-process interpretation), or
- the generic’s solid form matches a claimed form, or
- the generic is marketed with a method-of-use that reads on claims.
Risk drivers in US litigation
- “Product-by-process” language: courts may examine whether the final product is distinguishable.
- Claim breadth: if independent claims are broad and dependent claims narrow, plaintiffs may choose the broadest theory supported by prosecution history.
What Paragraph IV challenge landscape could involve US 3,553,212?
Short answer: A Paragraph IV risk analysis depends on:
- whether US 3,553,212 is Orange Book-listed for an NDA/BLA
- which generics have filed ANDA/BLA certifications referencing it
- whether settlements occurred that delayed generic launch
If there are known ANDA filings
A litigation and settlement timeline typically includes:
- Notice letters (Paragraph IV)
- Case numbers (Hatch-Waxman)
- Settlement dates and 180-day exclusivity triggers
- Launch dates impacted by preliminary injunctions or stay orders
What patent litigation affects US 3,553,212?
Short answer: Litigation must be sourced from dockets tied to:
- the patent number (US 3,553,212)
- Hatch-Waxman case names involving the Orange Book listing (if any)
- infringement assertions by the assignee/owner
How to evaluate litigation posture
- Claim construction rulings that narrow or broaden claim meaning
- Validity outcomes (anticipation, obviousness, indefiniteness, written description, enablement)
- Infringement outcomes tied to specific product lots or process evidence
How does US 3,553,212 compare with other patents in the same therapeutic area?
Short answer: Comparison is claim-based:
- Does it cover the active ingredient itself or only a manufacturing route?
- Are later patents (same family) broader or narrower?
- Do competitor portfolios cover alternative crystalline forms, analogs, or different routes?
What to map across competitors
- Same scaffold or formula space
- Salt/polymorph coverage breadth
- Process condition overlap
- Potential overlap with regulatory filings (NDA paragraph IV references)
Key Takeaways
- US 3,553,212’s enforceable scope is defined by its verbatim independent and dependent claim language, and by whether it is a compound, process, formulation, or method-of-use patent.
- Practical risk for competitors depends on Orange Book listing status and any existing Hatch-Waxman litigation/settlements tied to the patent.
- A credible freedom-to-operate conclusion requires claim-by-claim element mapping to the target product’s composition, solid form, and manufacturing steps, plus a family-wide review of related continuations/divisionals.
FAQs
- How do product-by-process claim terms affect infringement analysis for manufacturing patents like US 3,553,212?
- What does it mean if a dependent claim requires a specific salt or polymorph, and how can generics design around it?
- How does PTA or pre-URAA filing status change the expiration date of a US patent such as 3,553,212?
- What factors determine whether US 3,553,212 would be used in a Paragraph IV certification?
- How do claim construction rulings in earlier cases influence the scope of US 3,553,212 in later disputes?
References
- (No patent text, prosecution history, assignee, filing date, Orange Book listing, or litigation docket details were provided, so no citable sources can be generated.)
More… ↓
⤷ Start Trial
|
